RATIONALE: Superoxide dismutase (SOD) 3 inhibits oxidative fragmentation of lung matrix components collagen I, hyaluronan, and heparan sulfate. Inherited change in SOD3 expression or function could affect lung matrix homeostasis and influence pulmonary function. OBJECTIVES: To identify novel SOD3 polymorphisms that are associated with lung function or chronic obstructive pulmonary disease (COPD). METHODS: Resequencing of 182 individuals identified two novel polymorphisms, E1 (rs8192287) and I1 (rs8192288), in a conserved region of the SOD3 gene of potential relationship to lung function. We next genotyped 9,093 individuals from the Copenhagen City Heart Study for the polymorphisms and recorded spirometry, and admissions and deaths due to COPD during 26-year follow-up. Finally, we validated our findings in a cross-sectional analysis of 35,635 individuals from the Copenhagen General Population Study. MEASUREMENTS AND MAIN RESULTS: Genotyping the Copenhagen City Heart Study identified 35 E1/I1 homozygotes, 1,050 heterozygotes, and 8,008 noncarriers (Hardy-Weinberg equilibrium: P = 0.93). Using quadruple lung function measurements, we found that E1/I1 homozygotes had 7% lower FVC % predicted (P = 0.006) and 4% lower FEV(1) % predicted (P = 0.12) compared with noncarriers. In the Copenhagen General Population Study, E1/I1 homozygotes also had lower FVC % predicted than noncarriers (P = 0.03), confirming an association between E1/I1 genotype and reduced lung function. E1/I1 homozygotes had adjusted hazard ratios for COPD hospitalization and COPD mortality of 2.5 (95% confidence interval, 1.0-5.9) and 3.7 (95% confidence interval, 0.9-15), respectively; the results were independent of influence from the R213G allele of the SOD3 gene. CONCLUSIONS: We identified two novel polymorphisms in a conserved region of the SOD3 gene and show that individuals that are homozygous for these polymorphisms have reduced FVC % predicted in two large, population-based studies.
RATIONALE: Superoxide dismutase (SOD) 3 inhibits oxidative fragmentation of lung matrix components collagen I, hyaluronan, and heparan sulfate. Inherited change in SOD3 expression or function could affect lung matrix homeostasis and influence pulmonary function. OBJECTIVES: To identify novel SOD3 polymorphisms that are associated with lung function or chronic obstructive pulmonary disease (COPD). METHODS: Resequencing of 182 individuals identified two novel polymorphisms, E1 (rs8192287) and I1 (rs8192288), in a conserved region of the SOD3 gene of potential relationship to lung function. We next genotyped 9,093 individuals from the Copenhagen City Heart Study for the polymorphisms and recorded spirometry, and admissions and deaths due to COPD during 26-year follow-up. Finally, we validated our findings in a cross-sectional analysis of 35,635 individuals from the Copenhagen General Population Study. MEASUREMENTS AND MAIN RESULTS: Genotyping the Copenhagen City Heart Study identified 35 E1/I1 homozygotes, 1,050 heterozygotes, and 8,008 noncarriers (Hardy-Weinberg equilibrium: P = 0.93). Using quadruple lung function measurements, we found that E1/I1 homozygotes had 7% lower FVC % predicted (P = 0.006) and 4% lower FEV(1) % predicted (P = 0.12) compared with noncarriers. In the Copenhagen General Population Study, E1/I1 homozygotes also had lower FVC % predicted than noncarriers (P = 0.03), confirming an association between E1/I1 genotype and reduced lung function. E1/I1 homozygotes had adjusted hazard ratios for COPD hospitalization and COPD mortality of 2.5 (95% confidence interval, 1.0-5.9) and 3.7 (95% confidence interval, 0.9-15), respectively; the results were independent of influence from the R213G allele of the SOD3 gene. CONCLUSIONS: We identified two novel polymorphisms in a conserved region of the SOD3 gene and show that individuals that are homozygous for these polymorphisms have reduced FVC % predicted in two large, population-based studies.
Authors: Fei Gao; Jeffrey R Koenitzer; Jacob M Tobolewski; Dianhua Jiang; Jiurong Liang; Paul W Noble; Tim D Oury Journal: J Biol Chem Date: 2007-12-28 Impact factor: 5.157
Authors: Melissa L T Teoh-Fitzgerald; Matthew P Fitzgerald; Taylor J Jensen; Bernard W Futscher; Frederick E Domann Journal: Mol Cancer Res Date: 2011-11-07 Impact factor: 5.852
Authors: I C Sørheim; D L DeMeo; G Washko; A Litonjua; D Sparrow; R Bowler; P Bakke; S G Pillai; H O Coxson; D A Lomas; E K Silverman; C P Hersh Journal: COPD Date: 2010-08 Impact factor: 2.409
Authors: Mitsuharu Okutsu; Jarrod A Call; Vitor A Lira; Mei Zhang; Jean A Donet; Brent A French; Kyle S Martin; Shayn M Peirce-Cottler; Christopher M Rembold; Brian H Annex; Zhen Yan Journal: Circ Heart Fail Date: 2014-02-12 Impact factor: 8.790
Authors: Koustav Ganguly; Timothy M Martin; Vincent J Concel; Swapna Upadhyay; Kiflai Bein; Kelly A Brant; Leema George; Ankita Mitra; Tania A Thimraj; James P Fabisiak; Louis J Vuga; Cheryl Fattman; Naftali Kaminski; Holger Schulz; George D Leikauf Journal: Am J Respir Cell Mol Biol Date: 2014-11 Impact factor: 6.914
Authors: Wenbo Tang; Amy R Bentley; Stephen B Kritchevsky; Tamara B Harris; Anne B Newman; Douglas C Bauer; Bernd Meibohm; Patricia A Cassano Journal: Free Radic Biol Med Date: 2013-05-17 Impact factor: 7.376
Authors: John M Hartney; Timothy Stidham; David A Goldstrohm; Rebecca E Oberley-Deegan; Michael R Weaver; Zuzana Valnickova-Hansen; Carsten Scavenius; Richard K P Benninger; Katelyn F Leahy; Richard Johnson; Fabienne Gally; Beata Kosmider; Angela K Zimmermann; Jan J Enghild; Eva Nozik-Grayck; Russell P Bowler Journal: Circ Cardiovasc Genet Date: 2014-08-01